leon-nanodrugs GmbH announces Dr Pascale Clement new Chief Technology Officer

The appointment strengthens scientific excellence and growth strategy

leon-nanodrugs GmbH (“leon”), the Munich based nanotechnology drug development company, has recruited Dr Pascale Clement as its new Chief Technology Officer (CTO). Dr Clement joins leon from Catalent and brings with her more than 20 years of international drug development experience across the lifecycle from early stage development to commercial launch.

Dr Clement holds a doctorate in Pharmaceutical Development and her expansive career includes positions as a senior formulation scientist, head of pharmaceutical development and multiple director positions. In addition to a rigorous scientific approach, she brings expertise in bioavailability enhancement, development of various dosage forms and in project management.

Dr Clement said: “I am honoured to be a part of the leon team and there is so much knowledge, talent and dedication here. leon has already shown its capabilities in advancing nanotechnology and I look forward to accelerating our considerable progress in the coming months.”

Andrea Cusack, Chief Executive Officer at leon, said: “leon is advancing our industry and in order to build on our success to date we require the best people. That’s why we are excited that Dr Clement has joined leon. Her experience and expertise will help leon to reach its targets and continue its drive to ‘enable nano now’.”

About leon

leon delivers novel, validated and optimized solutions that create value for clients and provide better outcomes for their patients. It expedites API’s to deliver enhanced bioavailability, increased solubility and improved stability, revitalizes forgotten formulations and breathes new life into generics.

© leon-nanodrugs GmbH 2020
DisclaimerPrivacy PolicySite Notice